Table 3.
Pre- and postoperative status in secondary VS-related symptoms: facial spasm, tinnitus, trigeminus, vertigo and incidence of treatment-related side effects classified in Clavin-Dindo-Classification (CDC) [21]
| All (N = 901) |
Solid VS (N = 846) | Cystic VS (N = 55) |
p-value | ||
|---|---|---|---|---|---|
| preoperative clinical status | |||||
| Facial Spasm | 0 (0) | 0 (0) | 0 (0) | NA | |
| Tinnitus | 663 (74) | 619 (73) | 44 (80) | 0.343 | |
| Trigeminus | 94 (10) | 82 (10) | 12 (22) | 0.009 | |
| Vertigo | 549 (61) | 504 (60) | 45 (82) | < 0.001 | |
| postoperative clinical status | |||||
| Facial Spasm | 28 (3) | 28 (3) | 0 (0) | 0.407 | |
| Tinnitus | 264 (29) | 247 (29) | 17 (31) | 0.761 | |
| Trigeminus | 54 (6) | 48 (6) | 6 (11) | 0.133 | |
| Vertigo | 359 (40) | 340 (40) | 19 (35) | 0.478 | |
| Treatment Complications / Side Effects | 62 (7) | 60 (7) | 2 (4) | 0.577 | |
| Clavien-Dindo-Classification (CDC) | |||||
| 2 | 21 (2) | 20 (2) | 1 (2) | 1 | |
| 3a | 29 (3) | 28 (3) | 1 (2) | 1 | |
| 3b | 12 (1) | 12 (1) | 0 (0) | 1 | |
| > 4 | 0 (0) | 0 (0) | 0 (0) | NA | |
Values are presented as the number of patients (%) unless indicated otherwise. Significant p-values (< 0.05) are highlighted in bold